Avalo Therapeutics (AVTX) Retained Earnings (2014 - 2026)
Avalo Therapeutics' (AVTX) quarterly Retained Earnings came in at -$468.2 million in Q1 2026, down 192.52% YoY from $506.0 million in Q1 2025, and down 688558.82% on a QoQ basis from $68000.0 in Q4 2025.
Avalo Therapeutics (AVTX) Retained Earnings (2014 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 13 years of Retained Earnings data on file, last reported at -$468.2 million in Q1 2026.
- Quarterly Retained Earnings fell 192.52% year-over-year to -$468.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$468.2 million (down 192.52% YoY) and the FY2025 annual result came in at $68000.0, up 100.02% from the prior year.
- Retained Earnings eased to -$468.2 million in Q1 2026, from $68000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $508.8 million in Q2 2025 to a low of -$468.2 million in Q1 2026.
- A 5-year average of $13.8 million and a median of $68000.0 in 2025 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings soared 216.15% — and 2025, when it tumbled 222.14%.
- Tracing AVTX's Retained Earnings over 5 years: stood at -$303.8 million in 2022, then fell by 10.31% to -$335.1 million in 2023, then slipped by 10.48% to -$370.3 million in 2024, then jumped by 100.02% to $68000.0 in 2025, then tumbled by 688558.82% to -$468.2 million in 2026.
- The last three Retained Earnings figures came in at -$468.2 million (Q1 2026), $68000.0 (Q4 2025), and -$434.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | 953.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 953.70 Mn |
| Mar 31, 2026 | -468.15 Mn |
| Dec 31, 2025 | 68,000.00 |
| Sep 30, 2025 | -434.80 Mn |
| Jun 30, 2025 | 508.77 Mn |
| Mar 31, 2025 | 506.02 Mn |
| Dec 31, 2024 | -370.26 Mn |
| Sep 30, 2024 | 355.99 Mn |
| Jun 30, 2024 | 344.35 Mn |
| Mar 31, 2024 | 343.88 Mn |
| Dec 31, 2023 | -335.13 Mn |
| Sep 30, 2023 | 341.47 Mn |
| Jun 30, 2023 | 314.76 Mn |
| Mar 31, 2023 | 307.50 Mn |
| Dec 31, 2022 | -303.82 Mn |
| Sep 30, 2022 | -294.00 Mn |
| Jun 30, 2022 | -297.20 Mn |
| Mar 31, 2022 | -284.22 Mn |
| Dec 31, 2021 | -262.17 Mn |
| Sep 30, 2021 | -243.00 Mn |